Highlights Immunotech Biopharm Ltd

Equities

6978

KYG4721A1004

Delayed Hong Kong S.E. Other stock markets 11:15:55 03/07/2024 am IST			5-day change	1st Jan Change
3.39 ^HKD	+6.94%		+11.88%	-32.20%

21/06	Immunotech Biopharm Unit Sells 80 Million Yuan of Certificates of Deposit	MT
29/03	Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immunotech Biopharm Unit Sells 80 Million Yuan of Certificates of Deposit	21/06	MT
Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023	29/03	MT
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Immunotech Biopharm Obtains Clinical Trial Nod in China for Leukemia Drug	19/02	MT
Immunotech Biopharm Receives an Approval of the Investigational New Drug Application for Phase I Clinical Trial from the Centre for Drug Evaluation of the National Medical Products Administration for the aT19 Injection	19/02	CI
Immunotech Biopharm Ltd Announces First Patient Enrolled in the Phase II Clinical Trialfor Car-T-19 Injection	03/01	CI
Chinese Drug Regulator Accepts Immunotech Biopharm's Application for AT19 Injection	27/11	MT
Immunotech Biopharm Ltd Completes the First Patient Enrolment for its Phase I Clinical Trial for the Denocabtagene Ciloleucel Injection	07/11	CI
Immunotech Biopharm Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	27/23/27	CI
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
Immunotech Biopharm Obtains China Clinical Trial Approval for Lymphoma Treatment	22/23/22	MT
Immunotech Biopharm Ltd Obtains the Clinical Approval for the Denocabtagene Ciloleucel Injection from the National Medical Products Administration	21/23/21	CI
Immunotech Biopharm’s New Drug Application for Lymphoma Injection Accepted by Chinese Regulator	29/22/29	MT
Immunotech Biopharm Ltd. Receives Acceptance Notice for the Investigational New Drug Application for the Denocabtagene Ciloleucel Injection	28/22/28	CI
Immunotech Biopharm Sees $19.6 Million H1 Loss	26/22/26	MT
Immunotech Biopharm Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	26/22/26	CI
Immunotech Biopharm, NKY Medical Form Tumor Diagnostics JV in Shanghai	03/22/03	MT
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	25/22/25	CI
Immunotech Biopharm Seeks Clinical Trial Nod in China for B-Cell Lymphoma Treatment	04/22/04	MT
Immunotech Biopharm Ltd. Submittes the Communication Meeting Application of New Drug Clinical Trial for the Company's RC19D2 Injection Product	03/22/03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Immunotech Biopharm Ltd

Equities

6978

KYG4721A1004

Highlights

Filters